Limited-duration Teclistamab
Limited-duration Teclistamab
Recruiting · NCT05932680 · Registry updated 2026-10-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Limited-duration Teclistamab | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell myeloma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-10-05 | NCT05932680 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Abramson Cancer Center at Penn Medicine | 137 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Abramson Cancer Center at University of Pennsylvania | Philadelphia | United States | 11 |
| Columbia University | New York | United States | 1 |
| Thomas Jefferson University, Honickman Center | Philadelphia | United States | 2 |
| University of Arkansas for Medical Sciences | Little Rock | United States | 218 |
| University of Iowa Hospitals and Clinics | Iowa City | United States | 99 |